Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
Healthcare
$2.09 +2.96%
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
52W Low $1.58High $9.22
Volume 0.03M
Average 0.16M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$22.50M
FY 2025 · Annual
Net Income
-$22.23M
FY 2025 · Annual
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 16.39M | 21.71M | 18.68M | 10.29M |
| Selling, General & Admin | 3.82M | 3.27M | 6.48M | 12.2M |
| Operating Expenses | 20.21M | 24.97M | 25.16M | 22.5M |
| Depreciation & Amortization | 63.61K | 272.85K | 2.14M | 0 |
| EBITDA | (20.08M) | (24.43M) | (25.16M) | (22.21M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (20.21M) | (24.97M) | (25.16M) | (22.5M) |
| Operating Margin | — | — | — | — |
| Interest Income | 27.03K | 352.67K | 222.29K | 287.71K |
| Interest Expense | 16.2K | 43.64K | (18.72K) | 20.25K |
| Other Income / Expenses | 47.41K | 229.21K | (2.12M) | 267.46K |
| Income Before Tax | (20.16M) | (24.74M) | (27.28M) | (22.23M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 800 | 0 |
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (1.34) | (1.65) | (3.26) | (1.06) |
| EPS (Diluted) | (1.34) | (1.65) | (3.26) | (1.06) |
| 15.03M | 15.03M | 19.51M | 21.02M | |
| 15.03M | 15.03M | 19.51M | 21.02M |
ACTU Earnings Waterfall · TTM
NASDAQ:ACTU · Revenue to Net Income
Key Ratios
EPS$-0.99
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.6
P/S Ratio0.0
Analysis
$0 of revenue converted into -$21.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.99, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 8-K | Current report | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 |
How much revenue does ACTU generate?
Actuate Therapeutics Inc (ACTU) reported $0.00 of revenue in fiscal 2025.
Is ACTU profitable?
Actuate Therapeutics Inc (ACTU) reported -$22.23M of net income.
Continue the stock analysis
Jump to another research area for this company.